$671 MillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$13.88 - $83.57The lowest and highst price in the last 52 weeks.
-3.02xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$0.00 (0.0%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
|Market Cap||$671 Million|
|Enterprise Value||$828 Million|
|Dividend Yield||$0.00 (0.0%)|
|1 Year Return||-74.2%|
|Outstanding Shares||33.2 Million|
|Avg 30 Day Volume||1.05 Million|
|Earnings per Share||-$6.71|
|Price to Sales Ratio||2.32|
|Price to Book Ratio||-2.98|
|Revenue to Enterprise Value||2.57|
|EBIT to Enterprise Value||-5.1|
|Total Debt to Enterprise Value||0.69|
|Debt to Equity||-2.84|
|Gross Profit||$316 Million|
|Net Income||-$222 Million|
|Quarterly Earnings Growth (YoY)||-56.5%|
|Return on Equity||111.16%|
|Return on Assets||-42.74%|
|Return on Invested Capital||-43.42%|
SHENZHEN, China & ROCKVILLE, Md.--(BUSINESS WIRE)--HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced the appointment of Leigh MacConell, Ph.D., as...Business Wire, 5 months ago
NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and…GlobeNewswire, 6 months ago
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc. and certain of its officers, on behalf of shareholders… | Ja...MarketScreener, 6 months ago